Overcoming drug resistance in cancer

See allHide authors and affiliations

Science  02 Jan 2015:
Vol. 347, Issue 6217, pp. 38-39
DOI: 10.1126/science.347.6217.38-i

Cancer patients frequently develop drug resistance. Martz et al. devised a method of identifying pathways causing resistance in cancer cells and found that Notch signaling mediated resistance to drugs used in breast cancer and melanoma. Winter et al. also used this screening method for myeloproliferative neoplasms, which often have an activating mutation in the kinase JAK2 but are resistant to JAK inhibitors. They pinned the cause of this resistance to RAS, a signaling protein. Thus, screening entire signaling pathways instead of individual genes can identify new therapeutic targets that may be important in multiple types of drug-resistant cancers.

Sci. Signal. 7, ra121 and ra122 (2014).

Navigate This Article